Arcadia Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held on December 19, 2025. The meeting was attended by stockholders representing approximately 51% of the total outstanding shares of common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Three proposals were voted upon at the Annual Meeting:
- Proposal I: Election of Directors
- All three nominees (Albert Bolles, Ph.D., Kevin Comcowich, and Thomas J. Schaefer) were elected as Class I directors until the 2028 annual meeting.
- Each nominee received 559,827 votes "For," with approximately 64,000 to 65,000 votes "Withheld."
- Proposal II: Advisory Vote on Executive Compensation
- The proposal was approved by stockholders.
- Votes: 72,445 "For," 70,865 "Against," and 540 "Abstain."
- Proposal III: Ratification of Independent Registered Public Accountants
- The selection of Deloitte & Touche LLP for the year ending December 31, 2025, was ratified.
- Votes: 697,730 "For," 4,574 "Against," and 1,372 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting process.
Investor Verification Checklist
- Verify the definitive proxy statement filed on November 19, 2025, for detailed descriptions of the proposals.
- Confirm the total number of outstanding shares to validate the 51% attendance calculation.
- Review the specific terms of the executive compensation package approved in Proposal II.
- Check subsequent filings for the official appointment letter from Deloitte & Touche LLP.